We unite the leading researchers and cancer specialists of Fred Hutch and UW Medicine so you can take part in Merkel cell carcinoma (MCC) research through clinical trials not available everywhere.
Single dose of neoadjuvant ipilimumab and nivolumab in resectable melanoma with CD8+ cell imaging: Interim results of the C-IT Neo trial. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell ...
Long-term follow-up of patterns of melanoma early and late recurrence after adjuvant anti-PD1 therapy. Effects of malnutrition on cardiovascular outcomes in malignant melanoma patients treated with ...
A common pinworm medication may stop and reverse cancer growth in Merkel cell carcinoma, an aggressive form of skin cancer, according to research led by University of Arizona Cancer Center researchers ...
Cancer Research Institute, New York, NY, USA. The cancer cell therapy landscape continues to evolve rapidly. In 2024, the first approvals of tumour-infiltrating lymphocyte (TIL) and T cell receptor ...
A New York Times health reporter explains what clinical trials are, why they are important and how they can help inform us. Credit...Ricardo Tomás Supported by By Nina Agrawal Nina Agrawal is a health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results